Results of Shareholder Analysis

Summary by AI BETAClose X

CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of December 31, 2025, revealing significant holdings by Andrew Webb with 14.10%, Christopher McConville with 9.65%, Brian Murray with 9.49%, David Lawton with 9.28%, and Zeus Dynamic Opportunities Fund with 3.67%. Following recent share issuances, neither Linista Group Inc. nor Spreadex hold a disclosable stake. The company is preparing to initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeedâ„¢ in glioblastoma patients in Q1 2026.

Disclaimer*

UK 100

Latest directors dealings